The Diverge trial, a prospective, multi-center trial which enrolled 302 patients, is the largest study conducted to date with a drug-eluting stent specifically designed for treating bifurcation lesions.
Paul Buckman, CEO of Devax, said: “The Diverge data will help guide our development and registration strategy to deliver to the market the first drug-eluting stent specifically designed for bifurcation lesions.”